David Anderson, MD
Urology · Springfield, MONPI 1477594505
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,477 of the $10,708 with a category attached, or 60.5%. 31 manufacturers reported payments, led by Axonics, Inc. at 42.4% of the total. Reporting peaked in 2021 at $3,063 and has fallen 86.0% since, to $429 in 2025.
Across 226 payments — averaging $47.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axonics, Inc.$5K
- Intuitive Surgical$3K
- Neotract Inc.$1K
- Boston Scientific$621
- Astellas Pharma US Inc$345
- Johnson & Johnson$112
- plus $1K from 25 others
What the payments were for
- Consulting fees$4004%
- Speaking & faculty fees$4734%
- Travel & lodging$3,29531%
- Food & beverage$6,47760%
- Education$460%
- Gifts$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axonics, Inc. | 66 | $4,543 |
| Intuitive Surgical | 52 | $2,964 |
| Neotract Inc. | 4 | $1,082 |
| Boston Scientific | 22 | $621 |
| Astellas Pharma US Inc | 22 | $345 |
| Johnson & Johnson(2 entities) | 3 | $112 |
| AbbVie | 7 | $107 |
| Amgen | 6 | $100 |
| Calyxo, Inc. | 2 | $92 |
| Urogen Pharma, Inc. | 4 | $78 |
| Myriad Genetic Laboratories, Inc. | 4 | $77 |
| Ferring Pharmaceuticals Inc. | 3 | $69 |
| Vertex | 3 | $66 |
| Tolmar, Inc. | 3 | $54 |
| Teleflex LLC | 1 | $41 |
| Pfizer | 3 | $37 |
| Coloplast | 2 | $35 |
| AstraZeneca | 1 | $35 |
| Sumitomo Pharma America, Inc. | 2 | $32 |
| Tolmar Pharmaceuticals, Inc. | 2 | $29 |
| Medtronic | 1 | $25 |
| Novartis | 1 | $24 |
| Procept Biorobotics Corporation | 1 | $23 |
| KARL Storz Endoscopy-america | 1 | $18 |
| Civco Medical Instruments | 1 | $17 |
| Blue Earth Diagnostics | 1 | $17 |
| Photocure Inc | 1 | $14 |
| Olympus America Inc. | 1 | $14 |
| Davol Inc. | 1 | $13 |
| Bayer | 1 | $11 |
| Travere Therapeutics, Inc. | 4 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Axonics r-SNM System$2,139
- Da Vinci Surgical System$1,690
- Bulkamid$1,539
- UroLift$1,021
- Axonics$690
- EMBOLD Fibered$120
How this compares
$10,708 in reported general payments places this provider in the 85th percentile of 250 urology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 63 | $58,414 |
| Tamsulosin Hcl | 254 | $2,864 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 242 | $1,313 |
| Estradiol | 16 | $1,181 |
| Ciprofloxacin Hcl | 252 | $1,154 |
| Silodosin | 22 | $1,104 |
| Solifenacin Succinate | 31 | $793 |
| Finasteride | 93 | $742 |
| Oxybutynin Chloride | 57 | $707 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 21 | $470 |
| Cephalexin | 48 | $386 |
| Oxybutynin Chloride ErOxybutynin Chloride | 14 | $213 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 69 | $183 |
| Tramadol Hcl | 14 | $94 |
| Levofloxacin | 47 | $80 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $345 | $58,41463 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 250 urology providers in Missouri.
Other urology in Springfield
- Travis BullockSaint Louis$201K
- Michael JohnsonSaint Louis$160K
- Samuel KuykendallKansas City$141K
- Gerald ParkNorth Kansas City$136K
- Gurdarshan SandhuSaint Louis$101K
- Etai GoldenbergSt. Louis$95K
- Gregory McLennanSaint Louis$89K
- Majdee IslamSaint Peters$64K
- Gerald AndrioleSaint Louis$64K
- Charles JonesSaint Louis$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.